TCTR20220921005已完成不适用
Validation in clinical outcomes of acute myeloid leukemia patients harboring RUNX1 mutation: a single-center cohort study and meta-analysis
Siriraj Hospital Mahidol University0 个研究点目标入组 135 人开始时间: 2022年9月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 135
研究概览
简要总结
The study enrolled 135 patients divided into two groups based on the presence of RUNX1 mutation. Among them, 27 patients were RUNX1mut patients while 108 were RUNX1wt patients. The cohort is median age was 55 years interquartile range. However the patients in the RUNX1mut group were significantly older than those in the RUNX1wt group with median ages of 62 years and 53 years.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 18 Years（—）
- 性别
- All
入选标准
- •(1) Patients aged above 18 years
- •(2) Patients with de novo AML or secondary AML
- •(3) Patients with molecular mutation profile by next-generation sequencing
- •(4) Patients who signed informed consent of AML registry study (793/2560 (EC2)
排除标准
- •(1)Patients diagnosed acute promyelocytic leukemia (APL)
研究者
相似试验
Unknown
不适用
Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT01329471Hillel Yaffe Medical Center75
Unknown
1 期
Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AMLAcute Myeloid LeukemiaNCT03913312Ruijin Hospital150
已完成
4 期
Intensive compared with nonintensive chemotherapy in treating older patients with acute myeloid leukaemia or myelodysplastic syndromeAcute myeloid leukaemia or high-risk myelodysplastic syndromeMyeloid leukaemiaCancerISRCTN62207270eukaemia Research Fund (UK)217
招募中
2 期
Addition of sulfalasazine to chemotherapy for the treatment of AML in the elderly2024-513084-38-00Assistance Publique Hopitaux De Paris64
招募中
1 期
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02Acute Myeloid LeukemiaMyelodysplastic SyndromeNCT04167696Celyad Oncology SA27